What is PE-22-28?
PE 22-28 is a shortened seven-amino-acid spadin analogue studied in potassium-channel and behavioral research. It is not interchangeable with full-length spadin or chemically modified derivatives.
Mechanism & research focus
Patch-clamp experiments demonstrated inhibition of the TREK-1 potassium channel in engineered cells. The research compared sequence variants and terminal modifications, showing that seemingly small changes could alter channel activity.
What the research covers
A 2017 study characterized shortened spadin analogues using electrophysiology and preclinical stability and behavioral experiments. These data connect a defined peptide sequence to channel inhibition and animal-model effects.
What remains uncertain
An antidepressant-like animal behavior is not clinical evidence of treating depression. Human efficacy, pharmacokinetics and long-term safety were not established in the cited study. Exact sequence and chemical modifications matter when comparing the literature with a research vial.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity ↗
Electrophysiology and preclinical testing distinguish PE 22-28 from spadin and other analogues.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: PE-22-28 research guide ↗